These data demonstrate that the levels of P-IL-17RA are reduced while the levels of IL-17RA are increased in proliferative prostate cancer cells and keratinocytes, which may enhance IL-17 responsiveness. This evidence concerns the gene IL17RA and prostate carcinoma.